Tracked deals
29
29 tracked deals across 2020-2026.
Pharmaceuticals Buyers & Acquisitions in California
Buyer mix
Strategic-led
34 strategic · 4 pe
Top trend
Volume peaked in 2021
7 tracked deals announced in 2021.
Primary Insight
What Stands Out
- Rare disease and specialty pipeline expansion shows up repeatedly, including transactions involving therapies such as VYKAT XR (Prader-Willi syndrome) and VYKAT-related rare disease focus.
- Immunology and cell engager programs are a recurring theme, including Gilead’s acquisition of Ouro Medicines and its BCMAxCD3 T cell engager in Phase 1/2.
- Large-cap pharma participation is evident across the period, with buyers including Eli Lilly, Novo Nordisk, Gilead, and Bausch Health.
- California manufacturing and supply-chain assets are also targeted—examples include peptide manufacturing and a 503B outsourcing facility, plus Irvine drug product operations transferred into Forma Life Sciences, Inc.
- Deal structures often tie value to advancement through milestone payments, contingent value rights, or scheduled regulatory-dependent close timelines.
Build a buyer list for your Pharmaceuticals deal
Find buyers actively acquiring pharmaceuticals companies.
Find buyers like these for your dealBuyer Snapshot
Top Buyers
Illustrative buyers pulled from tracked transactions on this page. This table is capped and intentionally non-exhaustive.
| Buyer | # Deals | Focus | Type |
|---|---|---|---|
| ACEA Pharma, Inc. | 1 | Exempted Cayman-incorporated pharmaceutical entity within... | Strategic |
| ACEA Therapeutics, Inc. | 1 | Clinical-stage pharmaceutical company focused on developi... | Strategic |
| Audax Private Equity | 1 | Middle‑market private equity firm focused on buy‑and‑buil... | PE |
| Aurora Capital Partners | 1 | Middle‑market private equity firm focused on acquiring an... | PE |
| BHC Lyon Merger Sub, Inc. | 1 | Merger subsidiary used to conduct the tender offer and me... | Strategic |
| Bausch Health Americas, Inc. | 1 | Wholly owned Bausch Health subsidiary participating in th... | Strategic |
| Bausch Health Companies Inc. | 1 | Global diversified pharmaceutical company developing and ... | Strategic |
| BioSelective Capital Investments | 1 | Risk-capital / private investment firm focused on biophar... | PE |
| BioVie Inc. | 1 | Clinical-stage biopharmaceutical company developing thera... | Strategic |
| CarePartners Pharmacy | 1 | National specialty infusion and specialty pharmacy provid... | Strategic |
Acquisition Volume in Pharmaceuticals in California by Year
Last 7 years
Actual
Full-year estimate
Supporting Data
Recent Transactions
-
May 5, 2026
- Buyer
- ACEA Therapeutics, Inc., ACEA Pharma, Inc.
- Target
- ACEA Pharma, Inc.
- Seller
- Phoenix Asia Holdings Limited
- Industry
- Pharmaceuticals
- Location
- California, United States
- Type
- Buyout
Scilex Holding Company’s indirect subsidiaries ACEA Therapeutics, Inc. and ACEA Pharma, Inc. entered into a stock acquisition agreement with Phoenix Asia Holdings Limited to acquire 100% of ACEA Pharma. The transaction is valued at $1 billion and will issue Phoenix shares to ACEA Therapeutics, with Phoenix expected to be renamed the “Go-Forward Company” ACEA Pharma and listed on Nasdaq after closing.
-
March 27, 2026
- Buyer
- Gilead Sciences, Lakefront Biotherapeutics
- Target
- Ouro Medicines
- Industry
- Pharmaceuticals
- Location
- California, United States
- Type
- Buyout
Gilead Sciences entered into a definitive agreement to acquire Ouro Medicines for $1.675 billion upfront, with up to $500 million in additional milestone payments. The deal adds gamgertamig (OM336), a BCMAxCD3 T cell engager in Phase 1/2, to Gilead’s inflammation and immunology pipeline and completes the expansion of Ouro’s capabilities within T cell engager therapies for autoimmune diseases.
-
- Buyer
- Servier
- Target
- Day One Biopharmaceuticals, Inc.
- Industry
- Pharmaceuticals
- Location
- California, United States
- Type
- Buyout
Servier and Day One Biopharmaceuticals entered into a definitive agreement for Servier to acquire Day One for $21.50 per share in cash, valuing the deal at approximately $2.5 billion. The acquisition is expected to close in the second quarter of 2026 and is intended to strengthen Servier’s rare oncology and pediatric low-grade glioma positioning while expanding its clinical-stage pipeline.
-
- Buyer
- Swedish Orphan Biovitrum AB (publ) (Sobi)
- Target
- Arthrosi Therapeutics, Inc.
- Industry
- Pharmaceuticals
- Location
- California, United States
- Type
- Buyout
Swedish Orphan Biovitrum AB (Sobi) has completed its acquisition of Arthrosi Therapeutics, purchasing all outstanding shares of Arthrosi’s common stock and common stock equivalents. The deal adds pozdeutinurad (AR882), a once-daily oral URAT1 inhibitor in two fully enrolled Phase 3 studies for progressive and tophaceous gout.
-
February 4, 2026
- Buyer
- BioSelective Capital Investments, Shayan Enterprises, LLC
- Target
- BioDuro's Irvine drug product development and manufacturing operations (now Forma Life Sciences, Inc.)
- Seller
- BioDuro, Advent International
- Industry
- Pharmaceuticals
- Location
- California, United States
- Type
- Divestiture
BioSelective Capital Investments, together with Shayan Enterprises, LLC, acquired BioDuro’s drug product development and manufacturing operations in Irvine, California and formed Forma Life Sciences, Inc. The transaction transfers two U.S.-based oral solid dosage development and manufacturing facilities (≈65,000 sq ft and ≈40,000 sq ft) to the new Delaware-held company; BioDuro (an Advent portfolio company) sold the assets.
-
January 8, 2026
- Buyer
- Eli Lilly and Company
- Target
- Ventyx Biosciences
- Seller
- Entities affiliated with New Science Ventures, Ventyx directors and officers (including through voting/support agreements)
- Industry
- Pharmaceuticals
- Location
- California, United States
- Type
- Buyout
Eli Lilly and Company has entered into a definitive agreement to acquire Ventyx Biosciences for approximately $1.2 billion. The deal values Ventyx at $14.00 per share in cash and is expected to close in the first half of 2026, subject to shareholder and regulatory approvals.
-
November 17, 2025
- Buyer
- CarePartners Pharmacy
- Target
- National Drug Wholesale (NDW)
- Industry
- Pharmaceuticals
- Location
- California, United States
- Type
- Buyout
CarePartners Pharmacy, a national specialty infusion pharmacy based in Libertyville, Illinois, has acquired National Drug Wholesale (NDW), a Santa Clara, California–based pharmaceutical wholesaler and distributor. The deal expands CarePartners’ specialty distribution capabilities, strengthens its biosimilar supply chain and licensing footprint, and supports its payer- and manufacturer-focused cost-containment programs.
-
October 10, 2025
- Buyer
- Novo Nordisk A/S
- Target
- Akero Therapeutics
- Industry
- Pharmaceuticals
- Location
- California, United States
- Type
- Buyout
Akero Therapeutics announced it has entered into a definitive agreement to be acquired by Novo Nordisk A/S in a transaction valued at up to $5.2 billion in cash. Under the terms of the deal, Akero shareholders will receive $54.00 per share at closing plus a non-transferable Contingent Value Right (CVR) that could pay an additional $6.00 per share contingent on full U.S. regulatory approval of efruxifermin (EFX) for compensated cirrhosis associated with MASH.
-
September 11, 2025
- Buyer
- Bausch Health Companies Inc., Bausch Health Americas, Inc., BHC Lyon Merger Sub, Inc.
- Target
- DURECT Corporation
- Industry
- Pharmaceuticals
- Location
- California, United States
- Type
- Buyout
Bausch Health Companies Inc. completed its previously announced tender offer to acquire DURECT Corporation for $1.75 per share in cash, totaling about $63 million upfront. The deal also includes potential net sales milestone payments of up to $350 million in the aggregate related to larsucosterol, which expands Bausch Health’s hepatology pipeline for alcohol-associated hepatitis.
-
February 21, 2025
- Buyer
- Hims & Hers Health, Inc.
- Target
- US-based peptide facility (unnamed)
- Industry
- Pharmaceuticals
- Location
- California, United States
- Type
- Buyout
Hims & Hers Health, Inc. has acquired a US-based peptide manufacturing facility in California to further verticalize its supply chain and expand domestic capabilities for personalized medications. The acquisition, which closed in early February, strengthens Hims & Hers’ ability to meet growing consumer demand for personalized healthcare and peptide-based treatments.
-
September 12, 2024
- Buyer
- Hims & Hers
- Target
- MedisourceRx
- Seller
- Nivagen Pharmaceuticals
- Industry
- Pharmaceuticals
- Location
- California, United States
- Type
- Divestiture
Hims & Hers has acquired MedisourceRx, the FDA-registered 503B outsourcing facility and business unit of Nivagen Pharmaceuticals. Bourne Partners served as exclusive financial adviser to Nivagen; proceeds from the sale will allow Nivagen to complete a sterile injectables facility in California and advance its pipeline.
-
February 12, 2024
- Buyer
- Gilead Sciences, Inc.
- Target
- CymaBay Therapeutics, Inc.
- Industry
- Pharmaceuticals
- Location
- California, United States
- Type
- Buyout
Gilead Sciences, Inc. agreed to acquire CymaBay Therapeutics, Inc. for an equity value of approximately $4.3 billion, or $32.50 per share in cash. The acquisition adds CymaBay’s investigational lead asset seladelpar for the treatment of primary biliary cholangitis (PBC), complementing Gilead’s existing liver portfolio.
-
September 22, 2023
- Buyer
- Murphy Canyon Acquisition Corp., Unnamed institutional investor (private placement purchaser)
- Target
- Conduit Pharmaceuticals Limited
- Industry
- Pharmaceuticals
- Location
- California, United States
- Type
- Buyout
Murphy Canyon Acquisition Corp. (MURF) completed its previously announced business combination with Conduit Pharmaceuticals Limited, resulting in the combined company trading on Nasdaq under the ticker CDT and a pro forma enterprise value of approximately $720 million. A single institutional investor purchased $20.0 million of MURF units in a private placement, and the combined transaction and offering provided Conduit with roughly $20 million of cash (after redemptions, before transaction expenses).
-
June 26, 2023
- Buyer
- Shionogi Inc., Shionogi & Co., Ltd.
- Target
- Qpex Biopharma, Inc.
- Seller
- Qpex equityholders
- Industry
- Pharmaceuticals
- Location
- California, United States
- Type
- Buyout
Shionogi Inc., the U.S. subsidiary of Shionogi & Co., Ltd., entered into a definitive agreement to acquire San Diego-based clinical-stage antimicrobial developer Qpex Biopharma, Inc. The acquisition (upfront $100 million plus up to $40 million in milestones) brings Qpex's investigational beta-lactamase inhibitor xeruborbactam and expands Shionogi's infectious disease R&D capabilities and pipeline.
-
- Buyer
- Audax Private Equity
- Target
- Pyramid Laboratories, Inc.
- Industry
- Pharmaceuticals
- Location
- California, United States
- Type
- Growth capital
Audax Private Equity has made a growth investment in Pyramid Laboratories, Inc., a Costa Mesa, California-based CDMO that provides formulation development, analytical/stability testing, and aseptic fill-finish manufacturing for large-molecule biologics. The capital will support planned facility expansions to increase vial-filling capacity by more than 30% and syringe filling by more than 50%, and to scale Pyramid's clinical and commercial biologics manufacturing and service operations.
-
November 14, 2022
- Buyer
- Indivior PLC
- Target
- Opiant Pharmaceuticals, Inc.
- Industry
- Pharmaceuticals
- Location
- California, United States
- Type
- Buyout
Indivior PLC will acquire Opiant Pharmaceuticals, Inc. for $20.00 per share in cash (approximately $145 million aggregate) plus up to $8.00 per share in contingent value rights tied to OPNT003 revenue milestones. The acquisition strengthens Indivior's addiction-treatment portfolio by adding Opiant's OPNT003 intranasal opioid overdose candidate and earlier-stage pipeline assets, and is expected to be accretive after the second full year of OPNT003 launch.
-
- Buyer
- Mirum Pharmaceuticals, Inc.
- Target
- Satiogen Pharmaceuticals, Inc.
- Industry
- Pharmaceuticals
- Location
- California, United States
- Type
- Buyout
Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) acquired San Diego-based Satiogen Pharmaceuticals, obtaining Satiogen-owned IP and licensing payments related to LIVMARLI (maralixibat) and volixibat. The deal, funded via Mirum stock and roughly $2.8 million in cash, reduces Mirum's royalty obligations and consolidates the economics of its commercial and pipeline programs.
-
January 19, 2022
- Buyer
- UCB, Zinc Merger Sub, Inc.
- Target
- Zogenix, Inc.
- Industry
- Pharmaceuticals
- Location
- California, United States
- Type
- Buyout
UCB (Euronext: UCB) has agreed to acquire Zogenix, Inc. (NASDAQ: ZGNX) in a cash tender offer valuing the deal at up to approximately US$1.9 billion, consisting of US$26.00 per share in cash plus a contingent value right of up to US$2.00 per share tied to regulatory milestones. The acquisition adds Zogenix's FINTEPLA (fenfluramine) — an approved treatment for seizures associated with Dravet syndrome and under review for Lennox-Gastaut syndrome — to UCB's neurology and rare disease portfolio and is expected to expand UCB's epilepsy pipeline and global commercial reach.
-
October 11, 2021
- Buyer
- Supernus Pharmaceuticals, Inc.
- Target
- Adamas Pharmaceuticals, Inc.
- Seller
- Adamas Pharmaceuticals stockholders
- Industry
- Pharmaceuticals
- Location
- California, United States
- Type
- Buyout
Supernus Pharmaceuticals agreed to acquire Adamas Pharmaceuticals in a cash tender offer valued at approximately $400 million upfront plus up to $50 million in contingent value rights, for total consideration of about $450 million. The acquisition gives Supernus two marketed CNS products (GOCOVRI and Osmolex ER), diversifies its Parkinson’s disease portfolio and is expected to be accretive with material synergies in 2022.
-
October 11, 2021
- Buyer
- Element Materials Technology
- Target
- Nanosyn
- Industry
- Pharmaceuticals
- Location
- California, United States
- Type
- Buyout
Element Materials Technology acquired Nanosyn, a San Francisco Bay Area-based contract development and manufacturing organization (CDMO) focused on drug discovery and small-batch API manufacturing, to strengthen Element’s pharmaceuticals and biopharmaceutical services in North America. Nanosyn operates three Bay Area facilities and has a team of more than 75 scientists, and the deal expands Element’s end-to-end life sciences capabilities from discovery through clinical development and regulatory support.
-
- Buyer
- Hikma Pharmaceuticals PLC
- Target
- Custopharm Inc.
- Seller
- Water Street Healthcare Partners
- Industry
- Pharmaceuticals
- Location
- California, United States
- Type
- Buyout
Hikma Pharmaceuticals has agreed to acquire Custopharm Inc., a US-based generic sterile injectables company, from Water Street Healthcare Partners for an initial $375 million plus up to $50 million in contingent consideration. The acquisition adds Custopharm's 13 approved products, R&D capabilities and pipeline to Hikma's injectables franchise and is expected to be accretive to Hikma's Injectables operating margin.
-
August 13, 2021
- Buyer
- Recro Pharma, Inc.
- Target
- IRISYS
- Seller
- EPS Americas, Corp., IriSys, Inc., Continent Pharmaceuticals U.S., Inc.
- Industry
- Pharmaceuticals
- Location
- California, United States
- Type
- Buyout
Recro Pharma (NASDAQ: REPH) acquired San Diego–based CDMO IRISYS for approximately $49.85 million in cash, stock and a seller promissory note, transforming Recro into a bi‑coastal, full‑service CDMO. The acquisition expands Recro's capabilities (including aseptic fill/finish and lyophilization), diversifies its client base and adds near‑term revenue and backlog.
-
- Buyer
- Pace Analytical Life Sciences, LLC, Aurora Capital Partners
- Target
- Drug Delivery Experts, LLC
- Industry
- Pharmaceuticals
- Location
- California, United States
- Type
- Addon
Pace Analytical Life Sciences, a CDMO subsidiary of Pace Analytical Services (itself a portfolio company of Aurora Capital Partners), has acquired Drug Delivery Experts, LLC, a San Diego-based CDMO specializing in complex injectable formulations and drug‑device combination product development. The acquisition expands Pace’s injectable and long‑acting/extended‑release capabilities and brings DDE’s scientific leadership into Pace’s west‑coast operations as DDE transitions to the Pace brand.
-
June 11, 2021
- Buyer
- BioVie Inc.
- Target
- NeurMedix, Inc.
- Seller
- NeurMedix, Inc.
- Industry
- Pharmaceuticals
- Location
- California, United States
- Type
- Buyout
BioVie Inc. acquired the biopharmaceutical assets of privately held NeurMedix, including NE3107, an orally administered small-molecule inhibitor targeting neuroinflammation and insulin resistance. The deal paid NeurMedix shareholders newly issued BioVie shares and cash at closing, with additional contingent cash and equity payments tied to clinical and regulatory milestones; the acquisition expands BioVie's pipeline into neurodegenerative diseases and oncology.
-
May 24, 2021
- Buyer
- CoreRx, Inc.
- Target
- Nucleo Life Sciences
- Industry
- Pharmaceuticals
- Location
- California, United States
- Type
- Addon
CoreRx, Inc. has acquired Nucleo Life Sciences, a boutique CDMO based in San Rafael, California, expanding CoreRx’s US West Coast development presence and formulation capabilities. The deal, supported by CoreRx’s majority owner NovaQuest Private Equity and other shareholders, will integrate Nucleo’s Fast-to-Clinic formulation expertise (including spray-dried dispersions and NucleLoad) into CoreRx’s development and manufacturing platform.
-
October 22, 2020
- Buyer
- Pfizer (Hospital Business)
- Target
- Arixa Pharmaceuticals, Inc.
- Industry
- Pharmaceuticals
- Location
- California, United States
- Type
- Buyout
Pfizer’s Hospital Business acquired Arixa Pharmaceuticals to advance development of Arixa’s lead oral prodrug ARX-1796, a potential oral beta-lactamase inhibitor + antibiotic combination. Financial terms were not disclosed; Arixa was a virtual, asset-light company based in Palo Alto and was advised by Four Oaks Partners on the transaction.
-
August 31, 2020
- Buyer
- Nestlé Health Science (NHSc), Société des Produits Nestlé S.A. (SPN), Nestlé S.A.
- Target
- Aimmune Therapeutics
- Industry
- Pharmaceuticals
- Location
- California, United States
- Type
- Buyout
Nestlé Health Science (NHSc), via a Nestlé S.A. acquisition subsidiary (Société des Produits Nestlé S.A.), agreed to acquire Aimmune Therapeutics for USD34.50 per share in cash, valuing the company at approximately USD2.6 billion. NHSc already owned ~25.6% of Aimmune; the tender offer is expected to close in Q4 2020 and will expand Nestlé's portfolio with Aimmune's FDA-approved peanut allergy therapy Palforzia.
-
- Buyer
- LGM Pharma, New Harbor Capital
- Target
- Nexgen Pharma (formulation development and drug product contract manufacturing business)
- Seller
- Nexgen Pharma
- Industry
- Pharmaceuticals
- Location
- California, United States
- Type
- Divestiture
LGM Pharma has acquired the formulation development and drug product contract manufacturing business of Nexgen Pharma, expanding LGM's CDMO capabilities and U.S.-based manufacturing footprint. Financial support for the transaction was provided by private equity firm New Harbor Capital; Nexgen Pharma sold its pharmaceutical CDMO unit to allow the company to focus on other healthcare segments.
-
January 9, 2020
- Buyer
- Galecto, Inc.
- Target
- PharmAkea, Inc.
- Industry
- Pharmaceuticals
- Location
- California, United States
- Type
- Buyout
Copenhagen-headquartered Galecto Inc. (a Novo Seeds portfolio company) has merged with San Diego-based PharmAkea, Inc. The combined clinical-stage company will retain the Galecto name, be incorporated in the United States, and combine complementary pipelines in fibrosis and oncology to accelerate development of small-molecule and galectin-targeting therapeutics.
Full Export
Purchase this data
Get the full acquisitions list for this page as CSV + XLSX.
Build a buyer list for your Pharmaceuticals deal
Find buyers actively acquiring pharmaceuticals companies.
Frequently Asked Questions
What kinds of pharmaceutical acquisition targets are represented in California deals?
Targets range from clinical-stage biopharma companies (for pipeline expansion in areas like rare disease, hepatology, and immunology) to operational assets such as drug product development/manufacturing and FDA-registered 503B outsourcing facilities, plus specialty distribution/wholesale capabilities.
Which recurring buyers appear in these California pharmaceuticals acquisitions?
Recurring names include Gilead Sciences, Eli Lilly and Company, Novo Nordisk A/S, Bausch Health Companies Inc., and Neurocrine Biosciences, as well as private equity–linked activity such as Lakefront Biotherapeutics.
Are California deals focused only on therapeutics, or do they include manufacturing and distribution?
They include both. Examples on the page cover manufacturing-related acquisitions (e.g., peptide and 503B/outsourcing capacity) and distribution/supply-chain expansion (e.g., acquisition of National Drug Wholesale (NDW) by CarePartners Pharmacy).
What deal terms or value drivers show up in the California transactions?
Several deals feature value beyond a headline purchase price, including milestone payments and contingent value rights tied to regulatory approval, along with close timing subject to customary conditions and approvals.
Related Acquisition Pages
Pharmaceuticals Buyers & Acquisitions
Pharmaceuticals Buyers & Acquisitions in Canada
Private Equity-Backed Pharmaceuticals Buyers
Pharmaceuticals Acquisitions in 2026
Pharmaceuticals Acquisitions in 2025
Pharmaceuticals Acquisitions in 2024
Pharmaceuticals Acquisitions in 2023
Pharmaceuticals Acquisitions in 2022
Pharmaceuticals Acquisitions in 2021
Acquisitions in California
Private Equity-Backed Acquisitions in California
Acquisitions in California in 2026